H

Huakang Biomedical Holdings Co Ltd
HKEX:8622

Watchlist Manager
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Watchlist
Price: 0.184 HKD -0.54%
Market Cap: 92.1m HKD
Have any thoughts about
Huakang Biomedical Holdings Co Ltd?
Write Note

Huakang Biomedical Holdings Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Huakang Biomedical Holdings Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
K
876
K
1134
1120
O
6929

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Income from Continuing Operations
-ÂĄ5.8m
CAGR 3-Years
21%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
K
Kaisa Health Group Holdings Ltd
HKEX:876
Income from Continuing Operations
-HK$56.9m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
-5%
K
Kelfred Holdings Ltd
HKEX:1134
Income from Continuing Operations
HK$1.4m
CAGR 3-Years
N/A
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Arts Optical International Holdings Ltd
HKEX:1120
Income from Continuing Operations
HK$37.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
0%
O
OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Income from Continuing Operations
$45.1m
CAGR 3-Years
85%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Huakang Biomedical Holdings Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-5.8m CNY

Based on the financial report for Dec 31, 2023, Huakang Biomedical Holdings Co Ltd's Income from Continuing Operations amounts to -5.8m CNY.

What is Huakang Biomedical Holdings Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-66%

Over the last year, the Income from Continuing Operations growth was -88%. The average annual Income from Continuing Operations growth rates for Huakang Biomedical Holdings Co Ltd have been 21% over the past three years , -66% over the past five years .

Back to Top